Sarfaraz K. Niazi, PhD, explains FDA's new guidance on promotional labeling as well as challenges and insights into how this ...

On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from ...

The FDA approved a high-concentration, citrate-free version of Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), making it ...

Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) ...

April brought 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of ...

During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at ...

In an interview with Adam Colborn, JD, director of government relations for the Academy of Managed Care Pharmacy focuses on ...

The approval marks the sixth for a biosimilar referencing Herceptin (trastuzumab) for the treatment of HER2-positive breast ...

Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine ...

On this episode of Not So Different, The Center for Biosimilars® discusses all the conference coverage, adalimumab data, and ...

Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices.

Formycon, a Germany-based biosimilar manufacturer, shared that its revenues for 2023 were 83% higher than in 2022, reaching a ...